Payment overview · 2025
General Payments
$280.49
15 reported records · 7 companies
Healthcare provider profile · identity verified
George S Lawrence, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOUNTAIN HOME, AR · NPI 1245237528
Verified facts
What the public records show
CMS Open Payments records show George S Lawrence, M.D. received $280.49 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $128.38 | 45.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.82 | 14.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.73 | 14.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.94 | 7.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.22 | 7.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 5.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.51 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.27 | 14 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $82.96 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $82.96 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $60.67 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.42 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 524 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 90 |
| Lisinopril | Lisinopril | 337 | 72 |
| Losartan Potassium | Losartan Potassium | 337 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 286 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 69 |
| Omeprazole | Omeprazole | 244 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 235 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 59 |
| Meloxicam | Meloxicam | 212 | 60 |
| Gabapentin | Gabapentin | 205 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 44 |
| Trazodone Hcl | Trazodone Hcl | 171 | 42 |
| Nifedipine Er | Nifedipine | 166 | 28 |
| Sertraline Hcl | Sertraline Hcl | 166 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 66 |
| Metformin Hcl | Metformin Hcl | 154 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 35 |
| Alendronate Sodium | Alendronate Sodium | 136 | 34 |
| Potassium Chloride | Potassium Chloride | 134 | 32 |
| Simvastatin | Simvastatin | 133 | 28 |
| Furosemide | Furosemide | 130 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 30 |
| Atenolol | Atenolol | 113 | 21 |
| Famotidine | Famotidine | 108 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 105 | 105 |
| Ezetimibe | Ezetimibe | 103 | 23 |
| Eliquis | Apixaban | 102 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 22 |
| Metformin Hcl Er | Metformin Hcl | 94 | 21 |
| Jardiance | Empagliflozin | 90 | 15 |
| Carvedilol | Carvedilol | 82 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 18 |
| Warfarin Sodium | Warfarin Sodium | 80 | 14 |
| Donepezil Hcl | Donepezil Hcl | 79 | 14 |
| Allopurinol | Allopurinol | 77 | 21 |
| Methylprednisolone | Methylprednisolone | 75 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 21 |
| Bupropion Xl | Bupropion Hcl | 74 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 70 | 52 |
| Tramadol Hcl | Tramadol Hcl | 70 | 23 |
| Montelukast Sodium | Montelukast Sodium | 69 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 55 |
| Clonazepam | Clonazepam | 64 | 20 |
| Ozempic | Semaglutide | 62 | 11 |
| Alprazolam | Alprazolam | 59 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 30 |
| Spironolactone | Spironolactone | 54 | 11 |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 52 | 52 |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 49 | 48 |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Prednisone | Prednisone | 40 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 35 |
| Estradiol | Estradiol | 36 | 14 |
| Topiramate | Topiramate | 36 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 12 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 24 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Acyclovir | Acyclovir | 18 | 13 |
| Diazepam | Diazepam | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $280.49 · 15 records | PFIZER INC. | ABRYSVO, AIRSUPRA, Auvelity, CAPVAXIVE, COMIRNATY, ELIQUIS, FREESTYLE LIBRE, FREESTYLE LIBRE 3, GARDASIL 9, Kerendia, NURTEC ODT, PENBRAYA, PREVNAR 20, QULIPTA, TRUMENBA, UBRELVY, VAXNEUVANCE, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error